Iodixanol adverse reactions were rare, and severe fatal adverse reactions were seldom reported. Consequently, the authors conclude that the potential adverse reaction risk of iodixanol contrast agent should be taken into consideration in future endeavors, and the skin and allergy of patients should be monitored following DSA. In an allergy, prompt and proactive treatment is essential to prevent worsening and dissemination.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- early onset
- magnetic resonance
- atopic dermatitis
- computed tomography
- optical coherence tomography
- prognostic factors
- adverse drug
- magnetic resonance imaging
- patient reported outcomes
- soft tissue
- risk assessment
- combination therapy
- replacement therapy
- electron transfer